ACSH has today submitted a letter to the FDA s Center for Tobacco Products, urging the agency to reconsider its opposition to tobacco harm reduction, an approach that uses modified risk tobacco products, including electronic cigarettes (e-cigarettes), to help smokers quit. The letter, supported by a number of ACSH s scientific advisors, explains the benefits of a harm reduction paradigm and notes the absence of logic in the FDA s hyper-precautionary stance, especially toward e-cigarettes.
ACSH has today submitted a letter to the FDA s Center for Tobacco Products, urging the agency to reconsider its opposition to tobacco harm reduction, an approach that uses modified risk tobacco products, including electronic cigarettes (e-cigarettes), to help smokers quit. The letter, supported by a number of ACSH s scientific advisors, explains the benefits of a harm reduction paradigm and notes the absence of logic in the FDA s hyper-precautionary stance, especially toward e-cigarettes. Considering the well-established risks of smoking and the enormous difficulty of quitting tobacco cigarettes, the FDA s warnings against e-cigarettes do far more harm than good.
Read the letter in its entirety here.
Category
